本帖最后由 StephenW 于 2012-7-7 14:41 编辑
PLoS One. 2011; 6(10): e25525. Published online 2011 October 5. doi: 10.1371/journal.pone.0025525
PMCID: PMC3187796
Praziquantel Facilitates IFN-γ-Producing CD8+ T Cells (Tc1) and IL-17-Producing CD8+ T Cells (Tc17) Responses to DNA Vaccination in Mice
Qiang Zou,1 Xin Yao,2 Jin Feng,3 Zhinan Yin,4 Richard Flavell,5 Yanxin Hu,6 Guoxing Zheng,7 Jin Jin,1 Youmin Kang,1 Bing Wu,1 Xiaoxuan Liang,1 Congcong Feng,1 Hu Liu,1 Weiyi Li,1 Xianzheng Wang,1 Yumei Wen,2 and Bin Wang1,2,*
1State Key Laboratory for Agro-Biotechnology, College of Biological Science, China Agricultural University, Beijing, People's Republic of China
2Key Laboratory of Medical Molecular Virology of MOH and MOE, Fudan University Shanghai Medical College, Shanghai, People's Republic of China
3Center for Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing, People's Republic of China
4College of Life Sciences, Nankai University, Tianjin, People's Republic of China
5Department of Immunobiology, Yale School of Medicine, New Haven, Conneticut, United States of America
6College of Veterinary Medicine, China Agricultural University, Beijing, People's Republic of China
7Department of Biomedical Sciences, University of Illinois College of Medicine, Rockford, Illinois, United States of America
* E-mail: [email protected]
Abstract
BackgroundCD8+ cytotoxic T lymphocytes (CTLs) are crucial for eliminating hepatitis B virus (HBV) infected cells. DNA vaccination, a novel therapeutic strategy for chronic virus infection, has been shown to induce CTL responses. However, accumulated data have shown that CTLs could not be effectively induced by HBV DNA vaccination.
Methodology/Principal FindingsHere, we report that praziquantel (PZQ), an anti-schistoma drug, could act as an adjuvant to overcome the lack of potent CTL responses by HBV DNA vaccination in mice. PZQ in combination with HBV DNA vaccination augmented the induction of CD8+ T cell-dependent and HBV-specific delayed hypersensitivity responses (DTH) in C57BL/6 mice. Furthermore, the induced CD8+ T cells consisted of both Tc1 and Tc17 subtypes. By using IFN-γ knockout (KO) mice and IL-17 KO mice, both cytokines were found to be involved in the DTH. The relevance of these findings to HBV immunization was established in HBsAg transgenic mice, in which PZQ also augmented the induction of HBV-specific Tc1 and Tc17 cells and resulted in reduction of HBsAg positive hepatocytes. Adoptive transfer experiments further showed that PZQ-primed CD8+ T cells from wild type mice, but not the counterpart from IFN-γ KO or IL-17 KO mice, resulted in elimination of HBsAg positive hepatocytes.
Conclusions/SignificanceOur results suggest that PZQ is an effective adjuvant to facilitate Tc1 and Tc17 responses to HBV DNA vaccination, inducing broad CD8+ T cell-based immunotherapy that breaks tolerance to HBsAg
CD8 +细胞毒性T淋巴细胞(CTL)的消除乙肝病毒(HBV)感染细胞的关键。已经表明,慢性病毒感染的一种新的治疗策略,DNA疫苗诱导CTL反应。但是,积累的数据表明,淋巴细胞不能有效地诱导HBV DNA疫苗。
方法/主要结果
在这里,我们报告说,吡喹酮(PZQ),的反schistoma药物,可作为辅助,以克服由乙型肝炎病毒DNA疫苗在小鼠体内缺乏强有力的CTL反应。 PZQ增强结合HBV DNA疫苗诱导的CD8 + T细胞依赖性和HBV特异性迟发型超敏反应反应(DTH)的在C57BL / 6小鼠。此外,诱导CD8 + T细胞Tc1和TC17亚型。使用γ-干扰素基因敲除(KO)小鼠IL-17 KO小鼠,两种细胞因子被发现在参与的DTH。这些研究结果的相关性乙肝疫苗接种,建立HBsAg转基因小鼠,PZQ在这也增加了诱导的HBV特异性TC1,TC17细胞导致HBsAg阳性肝细胞减少。继转移实验进一步表明,PZQ的引物从野生型小鼠的CD8 + T细胞,但不是从γ-干扰素KO或IL-17 KO小鼠的对口,导致在消除乙肝表面抗原阳性的肝细胞。
结论/意义
我们的研究结果表明PZQ是一种有效的辅助,以促进Tc1和TC17 HBV DNA疫苗的反应,引起广泛的CD8 + T细胞为基础的免疫疗法,打破容忍对HBsAg
|